INSM vs. KYMR: Insmed vs. Kymera Therapeutics Stock Comparison
How do Insmed (INSM) and Kymera Therapeutics (KYMR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Insmed (INSM) and Kymera Therapeutics (KYMR) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
Insmed (INSM) has more than two decades of public-market history since June 1, 2000, whereas Kymera Therapeutics (KYMR) listed on August 21, 2020 and has a much shorter record to draw on.
| Profile Item | INSM | KYMR |
|---|---|---|
| Name | Insmed Incorporated | Kymera Therapeutics Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 25.10 billion USD | 11.25 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | June 1, 2000 | August 21, 2020 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | INSM | KYMR |
|---|---|---|
| Total Return (1Y) | -39.17% | 131.52% |
| Total Return (3Y, Annualized) | 70.17% | 111.65% |
| Total Return (5Y, Annualized) | 28.96% | 15.68% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | INSM | KYMR |
|---|---|---|
| Volatility (1Y, Annualized) | 63.09% | 62.83% |
| Beta (5Y) | 0.80 | 2.00 |
| Max Drawdown (5Y) | -56.54% | -83.27% |
| Avg. Volume (3M) | 2.76M | 833.05K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | INSM | KYMR |
|---|---|---|
| Sharpe Ratio (1Y) | -0.69 | 2.03 |
| Sortino Ratio (1Y) | -1.04 | 4.16 |
Profitability
ROE (TTM)
Both Insmed (INSM) at -72.45% and Kymera Therapeutics (KYMR) at -27.29% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-72.45%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- INSM
- -72.45%
- Min
- -167.77%
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
-27.29%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- KYMR
- -27.29%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Insmed (INSM) reports a negative net margin of -39.85%, usually indicating a net loss over the period. Meanwhile Kymera Therapeutics (KYMR) reports 0.00%, ranking against industry peers normally.
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-39.85%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
- INSM
- -39.85%
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 18.05%
- Q3
- 4.78%
- KYMR
- 0.00%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Insmed (INSM) at -15.60% and Kymera Therapeutics (KYMR) at -396.04% report negative operating margin values, usually indicating operating losses over the period.
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-15.60%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- INSM
- -15.60%
- Q1
- -78.82%
- Min
- -207.40%
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
-396.04%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
- KYMR
- -396.04%
Profitability Metrics
| Metric | INSM | KYMR |
|---|---|---|
| ROE (TTM) | -72.45% | -27.29% |
| ROA (TTM) | -17.25% | -17.64% |
| Net Margin (TTM) | -39.85% | 0.00% |
| Operating Margin (TTM) | -15.60% | -396.04% |
| Gross Margin (TTM) | 84.40% | 0.00% |
Growth
Revenue Growth
Insmed (INSM) at 66.73% sits in the top revenue growth quartile, while Kymera Therapeutics (KYMR) at -16.70% is in the bottom quartile, showing a clear gap in revenue momentum.
EPS Growth
Neither Insmed (INSM) nor Kymera Therapeutics (KYMR) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | INSM | KYMR |
|---|---|---|
| Revenue Growth (YoY) | 66.73% | -16.70% |
| Revenue Growth (3Y CAGR) | 35.20% | -5.74% |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Both Insmed (INSM) at 2.86 and Kymera Therapeutics (KYMR) at 11.13 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.86
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- INSM
- 2.86
- Q1
- 2.47
- Min
- 0.10
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
11.13
- Max
- 25.13
- Q3
- 12.13
- KYMR
- 11.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Kymera Therapeutics (KYMR) at 0.05 carries an industry-typical debt-to-equity mix, while Insmed (INSM) at 1.01 uses more debt funding than most peers.
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.01
- Max
- 1.42
- INSM
- 1.01
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.05
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- KYMR
- 0.05
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | INSM | KYMR |
|---|---|---|
| Current Ratio (MRQ) | 2.86 | 11.13 |
| Debt / Equity (MRQ) | 1.01 | 0.05 |
| Net Debt / EBITDA | -- | -- |
Dividends
Dividend Yield (TTM)
Neither Insmed (INSM) nor Kymera Therapeutics (KYMR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- INSM
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- KYMR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Insmed (INSM) nor Kymera Therapeutics (KYMR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- INSM
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- KYMR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | INSM | KYMR |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Neither Insmed (INSM) nor Kymera Therapeutics (KYMR) reports a P/E ratio value for this period, so a direct comparison isn’t possible.
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- INSM
- --
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- KYMR
- --
P/S Ratio (TTM)
Insmed (INSM) at 16.52 prices around its industry’s typical P/S ratio, while Kymera Therapeutics (KYMR) at 110.00 clears its benchmark range — KYMR looks notably rich on sales.
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.52
- Max
- 58.18
- Q3
- 25.77
- INSM
- 16.52
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
110.00
- KYMR
- 110.00
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Both look rich against book: Kymera Therapeutics (KYMR) at 6.96 sits in the upper P/B ratio quartile, and Insmed (INSM) at 34.55 prices even higher, above its industry range.
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
34.55
- INSM
- 34.55
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.96
- Max
- 13.53
- KYMR
- 6.96
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | INSM | KYMR |
|---|---|---|
| P/E Ratio (TTM) | -- | -- |
| P/S Ratio (TTM) | 16.52 | 110.00 |
| P/B Ratio (MRQ) | 34.55 | 6.96 |
| Free Cash Flow Yield (TTM) | -1.82% | -1.46% |